NOVO — Februar 2026
-
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly https://www.fool.com/investing/2026/02/20/novo-nordisk-stock-great-news-eli-lilly/
-
The ‘Last 20 Pounds’ Pill The new Wegovy is for people who never thought they would use a GLP-1. https://www.thecut.com/article/new-wegovy-pill-users-postpartum-menopause.html?utm_source=twitter&utm_medium=s1&utm_campaign=nym
-
Endnu engang interessant at se ind i, hvordan andre mennesker i en anden kulturkreds tænker og handler: Her 40 årige kvinder i USA, der ønkser at tabe sig, så de bliver "set" af andre (ikke specielt sexuelt) på arbejde, i fritiden mv. - Der er helt overordnet et andet pres på kvinder i USA i forhold til f.eks Europa, hvor der også er et "naturligheds" ideal og en generel mere woke indstilling... Artiklen emmer af lettelse og eufori: - Det bliver stort i USA.
-
Den kræver ikke abonnement Pauly?
-
Ok.
-
More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds https://www.reuters.com/business/healthcare-pharmaceuticals/more-than-third-patients-wegovy-pill-are-new-glp-1-drugs-study-finds-2026-02-11/
-
The ‘Last 20 Pounds’ Pill The new Wegovy is for people who never thought they would use a GLP-1. https://www.thecut.com/article/new-wegovy-pill-users-postpartum-menopause.html?utm_source=twitter&utm_medium=s1&utm_campaign=nym
-
GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies https://eu.usatoday.com/story/money/2026/02/22/wegovy-challenges-hims-weight-loss-drug-copycats/88662632007/
-
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 https://www.fool.com/investing/2026/02/22/2-unstoppable-dividend-stocks-to-buy-right-now-for/
-
Godmorgen
-
Novo Nordisk: Hvad kommer HIMS til at sige om compounding? https://proinvestor.com/boards/131258
-
Danske aktier i USA: Novo og Genmab endte under niveau i København https://proinvestor.com/investornyt/1414038/danske-aktier-i-usa-novo-og-genmab-endte-under-niveau-i-kobenhavn
-
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved https://ml-eu.globenewswire.com/Resource/Download/813a1be1-6fe0-4cf0-9f2e-337f8f2639e1
-
Av av! Det sgu altid farligt at lave den slags studier, hvor man head-to-head sammenligner med en konkurrent.. Det er værd at bemærke forskellen på dosis, så lad os nu se hvis de forsøger med højere dosis af Cagrisema.. Alt i alt, ser det ud til at ja stofferne generelt er meget afhængig af at man finder den rette dosis hvis målet udelukkende er det højeste vægttab.. ja os derfor vi ser at semaglutid forsøges med højere dosis..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind